A new market research study, titled “Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” has been published by Transparency Market Research, providing a comprehensive analysis of the market. The major driving factors, barriers, and current trends of the global hospital infection therapeutics market have been included in the scope of the research report.
Browse the full Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report at http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html
As per the research study, in 2013, the global market for hospital infection therapeutics was valued at US$3.1 bn and is estimated to reach US$3.6 bn by the end of 2020. The market is predicted to exhibit a 3.10% CAGR between 2014 and 2020.
Hospital-acquired infections are majorly caused by fungal, bacterial, and viral pathogens. Several cases of hospital infections are acquired from the intensive care units of hospitals. A huge number of antimicrobial drugs have demonstrated their capability in treating a wide range of hospital infections. The increasing number of pipeline drug molecules in the hospital infection therapeutics market is one of the biggest opportunities for the growth of the market. In addition, the absence of skilled staff in developing and underdeveloped countries and growing prevalence of several hospital infections are the major factors expected to fuel the growth of the market in the next few years.
Based on the major prominent types of drugs in the market, the global market for hospital infection therapeutics has been segmented into antiviral, antibacterial, and antifungal drugs. In 2013, the antibacterial drugs segment dominated the market, accounting for a 70.7% share in the global market for hospital infection therapeutics. This segment is projected to grow at a fast pace in the next few years. The research study has further analyzed the major drugs in the pipeline, including Plazomicin, Ceftolozane, Delafloxacin, Eravacycline, Surotomycin, Tedizolid, Amikacin Inhale, MK-3415A, CAZ AVI, Dalvance, and Oritavancin.
On the basis of type of infection, the global market for hospital infection therapeutics has been categorized into gastrointestinal disorders, hospital-acquired pneumonia, urinary tract infections, surgical site infections, bloodstream infections, and other infections. In 2013, the hospital-acquired pneumonia segment accounted for a 20% share in the global market for hospital infection therapeutics. Nevertheless, the urinary tract infections segment is anticipated to grow rapidly in the near future.
Currently, North America leads the overall market and is estimated to remain in the leading position in the next few years. North America is closely trailed by Europe. The rapid growth of these two regional markets can be attributed to the increasing healthcare awareness and growing demand for advanced drugs. On the other hand, the Asia Pacific market for hospital infection therapeutics is estimated to witness the fastest growth throughout the forecast period.
Furthermore, the research report talks about the competitive scenario of the global market for hospital infection therapeutics. Detailed profiles of the prominent players have been discussed in the scope of the research study. Some of the leading players operating in the market are Bayer AG, Johnson & Johnson Services, Inc., Actavis plc, Sanofi, Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc.
Key Segments of the Hospital Infection Therapeutics Market:
Hospital Infection Therapeutics Market, by Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
Hospital Infection Therapeutics Market, by Major Infections
- Hospital-Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
Hospital Infection Therapeutics Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Mr. Sudip. S
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453